Kengo Takeuchi

Summary

Affiliation: The University of Tokyo
Country: Japan

Publications

  1. pmc KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
    Yuki Togashi
    Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    PLoS ONE 7:e31323. 2012
  2. pmc Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
    Junko Nomoto
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    BMC Cancer 12:457. 2012
  3. doi request reprint RET, ROS1 and ALK fusions in lung cancer
    Kengo Takeuchi
    Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Nat Med 18:378-81. 2012
  4. doi request reprint Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation
    Kengo Takeuchi
    The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Blood 116:5631-7. 2010
  5. pmc Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma
    Kengo Takeuchi
    Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research 3 8 31 Ariake, Koto, Tokyo 135 8550, Japan
    Haematologica 96:464-7. 2011
  6. doi request reprint Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
    Kengo Takeuchi
    Division of Pathology, The Cancer Institute, Tokyo, Japan
    Clin Cancer Res 14:6618-24. 2008
  7. doi request reprint Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification
    Kengo Takeuchi
    Pathology Project for Molecular Targets, Division of Pathology, Thoracic Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 17:3341-8. 2011
  8. doi request reprint KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
    Kengo Takeuchi
    The Cancer Institute, Japanese Foundation for Cancer Research, Japan
    Clin Cancer Res 15:3143-9. 2009
  9. doi request reprint EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    Kentaro Inamura
    Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research JFCR, Tokyo, Japan
    J Thorac Oncol 3:13-7. 2008
  10. ncbi request reprint Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
    Kazuhito Suzuki
    Department of Medical Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Leuk Lymphoma 54:2412-7. 2013

Detail Information

Publications36

  1. pmc KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
    Yuki Togashi
    Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    PLoS ONE 7:e31323. 2012
    ..This finding will broaden the potential value of archival FFPE tissues and provide further biological and clinical insights into ALK-positive lung cancer...
  2. pmc Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
    Junko Nomoto
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    BMC Cancer 12:457. 2012
    ..However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection...
  3. doi request reprint RET, ROS1 and ALK fusions in lung cancer
    Kengo Takeuchi
    Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Nat Med 18:378-81. 2012
    ....
  4. doi request reprint Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation
    Kengo Takeuchi
    The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Blood 116:5631-7. 2010
    ..However, LyGa is recognized as a pseudomalignant process because of its clinical characteristics. The concept of LyGa should be well recognized...
  5. pmc Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma
    Kengo Takeuchi
    Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research 3 8 31 Ariake, Koto, Tokyo 135 8550, Japan
    Haematologica 96:464-7. 2011
    ..SQSTM1-ALK may be a rare fusion, but our data provide novel biological insights and serve as a key for the accurate diagnosis of this rare lymphoma...
  6. doi request reprint Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
    Kengo Takeuchi
    Division of Pathology, The Cancer Institute, Tokyo, Japan
    Clin Cancer Res 14:6618-24. 2008
    ..To allow sensitive detection of EML4-ALK fusion transcripts, we have now developed a multiplex reverse transcription-PCR (RT-PCR) system that captures all in-frame fusions between the two genes...
  7. doi request reprint Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification
    Kengo Takeuchi
    Pathology Project for Molecular Targets, Division of Pathology, Thoracic Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 17:3341-8. 2011
    ..By using sensitive immunohistochemistry, therefore, we reassessed "ALK-negative" IMT cases defined with conventional immunohistochemistry (approximately 50% of all examined cases)...
  8. doi request reprint KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
    Kengo Takeuchi
    The Cancer Institute, Japanese Foundation for Cancer Research, Japan
    Clin Cancer Res 15:3143-9. 2009
    ..The sensitivity of EML4-ALK detection by immunohistochemistry should be increased adequately...
  9. doi request reprint EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    Kentaro Inamura
    Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research JFCR, Tokyo, Japan
    J Thorac Oncol 3:13-7. 2008
    ..Tumors featuring EML4-ALK fusion constitute one subtype of NSCLC that might be highly sensitive to ALK inhibitors. Herein, we present results of a first large scale study of EML4-ALK fusion in lung cancers...
  10. ncbi request reprint Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
    Kazuhito Suzuki
    Department of Medical Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Leuk Lymphoma 54:2412-7. 2013
    ..In conclusion, high TK activity was a strong predictor for short OS and poor response among patients with previously untreated DLBCL treated with R-CHOP...
  11. doi request reprint Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations
    Miyako Hiramatsu
    Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research JFCR, 3 8 31 Ariake, Koto ku, Tokyo 135 8550, Japan
    Lung Cancer 70:94-102. 2010
    ..The signal proteins were differently related to mutation status from cultured cells...
  12. doi request reprint Increased incidence of interstitial pneumonia by CHOP combined with rituximab
    Daisuke Ennishi
    Department of Oncology and Hematology, Cancer Institute Hospital, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Int J Hematol 87:393-7. 2008
    ..jirovecii and fungal infection. The need for prophylactic antifungals and ST during R-CHOP should be evaluated by randomized controlled trials...
  13. doi request reprint Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma
    Kazuhito Suzuki
    Department of Medical Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31 Ariake, Koto ku, Tokyo 1358550, Japan
    Jpn J Clin Oncol 43:37-44. 2013
    ..Prognostic predictors for newly diagnosed malignant lymphoma are well known. However, they have not been compared for patients with recurrent or refractory malignant lymphoma...
  14. doi request reprint EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
    Kentaro Inamura
    Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Koto ku, Tokyo, Japan
    Mod Pathol 22:508-15. 2009
    ....
  15. doi request reprint Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy
    Kyoko Ueda
    Department of Hematology Oncology, Cancer Institute Hospital, Tokyo, Japan
    Leuk Lymphoma 54:1928-33. 2013
    ..82%, p = 0.043). Patients with localized disease had significantly better 3-year PFS than those with advanced disease (94% vs. 73%, p = 0.026). Upon multivariate analysis, non-gastric lymphoma retained prognostic significance for PFS...
  16. doi request reprint Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma
    Yasuhito Terui
    Departments of Medical Oncology and Hematology, Division of Clinical Chemotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 15:2523-30. 2009
    ..With increasing use, resistance to rituximab is a continuing concern, but CD20 mutation as a cause of resistance has not previously been reported...
  17. pmc Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes
    Hironori Ninomiya
    Division of Pathology, The Cancer Institute, Ariake 3 8 31, Koutou ku, Tokyo 135 8550, Japan
    BMC Cancer 13:8. 2013
    ..EML4-ALK fusion confers a characteristic histology and is detected more frequently in never or light smokers and younger patients...
  18. pmc Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
    Masahiro Yokoyama
    Department of Hematology, Cancer Institute Hospital, 3 8 31 Ariake, Koto ku, Tokyo 135 8550, Japan
    ISRN Oncol 2013:863909. 2013
    ..We recommend rapid administration of rituximab for practice setting in patients with CD20+NHL being treated with rituximab or rituximab-containing chemotherapy. (Clinical trial no. JFCR2009-1027)...
  19. ncbi request reprint Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method
    Emiko Sugawara
    Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer 118:4427-36. 2012
    ..In this context, ALK inhibitor therapy would constitute a therapeutic advance, as has previously been demonstrated with lung cancer, inflammatory myofibroblastic tumors, and anaplastic large cell lymphomas...
  20. doi request reprint Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial
    Takashi Watanabe
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 29:3990-8. 2011
    ..To improve progression-free survival (PFS) in patients treated with R-CHOP as the primary end point, we conducted a phase III study...
  21. doi request reprint An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy
    Yuji Mishima
    Olympus Bio Imaging Laboratory, Clinical Chemotherapy, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 15:3624-32. 2009
    ....
  22. doi request reprint Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era
    Naoto Tomita
    Bay area Lymphoma Information Network, Tokyo, Japan
    Cancer Sci 103:245-51. 2012
    ..The efficacy and manner of CNS prophylaxis in patients for each involvement site should be evaluated further...
  23. ncbi request reprint Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan
    Hisakazu Nishimori
    Division of Medical Oncology and Hematology, Cancer Institute Hospital, Koto ku, Tokyo 135 8550, Japan
    Acta Med Okayama 64:285-91. 2010
    ..In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer...
  24. ncbi request reprint Implications for differential diagnosis of lung cancer-associated lymphadenopathy in lymphoepithelioid cell lymphoma (Lennert's lymphoma) arising simultaneously with lung cancer: a case report
    Rira Hoshi
    Department of Cytology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Acta Cytol 54:197-201. 2010
    ..We describe details from fine needle aspiration cytology (FNAC) of LCL in a patient simultaneously suffering from lung cancer, in whom extensive lymph node metastasis was suspected clinically...
  25. pmc A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients
    Kazuya Takamochi
    Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    PLoS ONE 8:e69794. 2013
    ..EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cancer. There is an urgent need to establish a rational diagnostic algorithm to identify this rare but important fusion in lung cancer...
  26. pmc R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
    Yuko Mishima
    Division of Hematology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31 Ariake, Koto ku, Tokyo, 135 8550, Japan
    Exp Hematol Oncol 1:30. 2012
    ..abstract:..
  27. doi request reprint Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma
    Hidenori Imai
    Department of Internal Medicine, Division of Hematology, Juntendo University School of Medicine, Tokyo, Japan
    Int J Hematol 89:673-8. 2009
    ..The 4-year overall survival rates by Kaplan-Meier analysis for Plk1-negative and positive patients were 80 and 38%, respectively (p = 0.02)...
  28. ncbi request reprint Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy
    Daisuke Ennishi
    Department of Medical Oncology and Hematology, Cancer Institute Hospital, Tokyo, Japan
    Am J Hematol 83:59-62. 2008
    ..Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients...
  29. ncbi request reprint Pathology of indolent B-cell neoplasms other than follicular lymphoma
    Seiji Sakata
    Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
    J Clin Exp Hematop 54:11-22. 2014
    ..In addition, a provisional subtype of low-grade B-cell lymphoma, "prolymphocytic/paraimmunoblastic lymphoma", is described. [J Clin Exp Hematop 54(1): 11-22, 2014]. ..
  30. ncbi request reprint Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease
    Natsuko Watanabe
    Ito Hospital, 4 3 6 Jingumae, Shibuya ku, Tokyo, Japan
    Br J Haematol 153:236-43. 2011
    ..The 5-year overall survival rate was 85% (95% confidence interval, 79-91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis...
  31. doi request reprint Carcinosarcomatous malignancy, osteosarcoma and squamous cell carcinoma, in giant cell tumor of the right distal femur
    Rikuo Machinami
    Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Ariake 3 10 6, Kouto ku, Tokyo 135 8550, Japan
    Pathol Res Pract 204:583-8. 2008
    ..Although secondary malignant giant cell tumor is known as a sarcoma arising at the site of a previously diagnosed giant cell tumor, this case should be regarded as a new type of secondary malignant giant cell tumor of bone...
  32. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
    ..The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS...
  33. doi request reprint Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
    Morio Yamamoto
    Department of Thoracic Surgery, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan
    Cancer Sci 103:390-2. 2012
    ..However, FISH studies failed to reveal EML4-ALK and KIF5B-ALK fusion genes in this BAC. These findings suggest the possibility that a novel or unknown ALK fusion gene plays a crucial role in BAC development...
  34. doi request reprint ERas is expressed in primate embryonic stem cells but not related to tumorigenesis
    Yujiro Tanaka
    Division of Regenerative Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan Department of Pediatric Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Cell Transplant 18:381-9. 2009
    ..Therefore, cynomolgus ES cells are more similar to human than mouse ES cells despite that ERas is expressed in cynomolgus and mouse ES cells but not in human ES cells...
  35. ncbi request reprint Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma
    Naoto Tomita
    Department of Hematology, Yokohama City University Medical Center, Japan, Yokohama, Japan
    Cancer 109:1146-51. 2007
    ..Peripheral T-cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis. In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B-cell lymphoma (DLBCL)...
  36. ncbi request reprint Secretion of interleukin-6 and vascular endothelial growth factor by spindle cell sarcoma complicating Castleman's disease (so-called 'vascular neoplasia')
    Chihiro Kakiuchi
    Department of Pathology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    J Pathol 197:264-71. 2002
    ..High levels of IL-6 and/or VEGF have been reported to play a role in CD. This is the first case report that clarifies the site of such cytokine production, showing the possibility of CD as a paraneoplastic phenomenon...